When an Acquiry organization seeks to implement a risk management process, they first need to identify the risks that are most common to their industry. These risks then need to be categorized into low, medium, and high risks according to their impact on the company. Once this information has been gathered from a variety of sources within the organization, the next step is to determine what type of risk management guide for acquisition should be used. For many programs managers, the best route is usually to go with a guide that addresses the key topics that pertain to the program manager’s area of expertise.
The fourth edition of the American Society of Clinical Pathologists’ (ASCP) Risk Management Guide for acquisition focuses on managing the risks that can result from drug manufacture and clinical administration. This guide was originally released in 1980 and has been through five editions since then. It is one of the most popular guides to use as a tool for clinical risk management.
The Risk Management Guide for acquisition was previously published as a volume in the eighth edition of the ASCP’s Transactions on Clinical Care (TCC). However, several changes were made to the guide for the sixth edition. These changes included updates on biotechnology and generic medications and revisions to the methodologies that are used to classify the different types of risks. The latest additions deal primarily with the area of biotechnology and the role it plays in the healthcare industry.
The risk management guide for acquisition process involves an assessment of the overall health of the company and the kind of future threats that might impact that health. The guide also discusses the financial aspects of the business and outlines the methods that should be used to mitigate any potential losses that might result. The guide also discusses the legal and ethical issues that need to be considered throughout the acquisition process. It provides data on how to conduct the due diligence analysis in order to determine the price that will be sufficient for the company to realize the proceeds from the sale of assets or the settlement of claims.
Another change made in the Risk management guide for the acquisition was the inclusion of a topic on medical device regulations. This topic is designed to educate physicians on the FDA (Food and Drug Administration) regulations that affect the manufacturing of medical devices and to educate them about the implications that such regulations might have for patient care. The guide for the acquisition process therefore makes it possible for physicians to acquire the necessary tools and information that they need in order to address the issues that may arise out of the regulations. This ensures that the acquisition process will go smoothly and that medical devices produced by legitimate companies will not encounter difficulty in gaining FDA approval.
Finally, the risk management guide for acquisition has made some significant updates to the information that should be made available to patients, buyers, vendors, and third parties during the clinical program review. This information includes the identification of the key stakeholders and the processes that they use in the health care industry, the current legislation that affect the industry, and the impact that any new legislation could have on the industry. This information allows the clinical programs to better meet their objectives. In addition, the updated guide for the acquisition process incorporates some key strategies that lead to the successful implementation of EHR software systems. The updated contents also enable healthcare organizations to become more effective at the development of EHR systems and at making sure that they are properly aligned with the systems when they are being developed and deployed.